Evidence map›Paper›PMID 40530879›Full record

ArticleMicrobiology spectrum2025

Oral delivery of GLP-1 peptide using recombinant

Zhiqiang Ke, Qianqian Ma, Xiaonan Ye, Yan Jin, Yanlin Wang, Xinyuan Zhao, Zhengding Su

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhiqiang KeProtein Engineering and Biopharmaceuticals science, Hubei University of Technology, Wuhan, China.ORCID 0009-0009-3454-9329
Qianqian MaProtein Engineering and Biopharmaceuticals science, Hubei University of Technology, Wuhan, China.
Xiaonan YeProtein Engineering and Biopharmaceuticals science, Hubei University of Technology, Wuhan, China.
Yan JinProtein Engineering and Biopharmaceuticals science, Hubei University of Technology, Wuhan, China.
Yanlin WangProtein Engineering and Biopharmaceuticals science, Hubei University of Technology, Wuhan, China.
Xinyuan ZhaoNational Demonstration Center for Experimental General Medicine Education, School of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, China.ORCID 0009-0007-1520-8620
Zhengding SuProtein Engineering and Biopharmaceuticals science, Hubei University of Technology, Wuhan, China.ORCID 0000-0003-3558-001X

Funding

Hubei Provincial Adminstration of Chinese Medicine ZY2023F149
6 · The paper itself

Abstract

Glucagon-like peptide-1 (GLP-1) is an effective therapeutic peptide for the treatment of type 2 diabetes mellitus (T2DM). Here, we constructed an effective probiotic-based oral GLP-1 delivery system by engineering the probiotic strain of

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide 1Lactobacillus gasseriAdministration, OralAnimalsHumansMaleMiceMice, Inbred C57BLProbioticsRatsRats, Sprague-DawleyGlucagon-Like Peptide 1advanced microbiome deliveryGLP-1 analogglucagon-like peptide-1gut microbiotaLactobacillus gasserioral deliveryprotein transduction domainserum albumin binding peptidetype 2 diabetes mellitus

Identifiers

PMID40530879
PMCPMC12323307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.